Cartesian Therapeutics, Inc.
RNAC · Nasdaq · United States
Share price · RNAC
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when RNAC's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 9 Nov 2026-6.8%
Nothing announced by RNAC that day or the session before.
- 6 Nov 2026+11.1%
- 15 Jun 2026-9.6%
Nothing announced by RNAC that day or the session before.
- 12 Jun 2026+18.0%
Nothing announced by RNAC that day or the session before.
- 10 Jun 2026+8.5%
- 9 Jun 2026+16.9%
- 9 Mar 2026+31.7%
- 5 Mar 2026-12.6%
Nothing announced by RNAC that day or the session before.
- 12 Jan 2026-11.3%
- Day beforeRegulation FD disclosure
- 22 Dec 2025-6.9%
Nothing announced by RNAC that day or the session before.
Share of unusual movement by asset
For each asset, the share of RNAC's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Descartes-08events and moves | 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 1% |
| Other company news (earnings, financing, releases naming no asset) | — | 24% |
| Sessions with no dated event | — | 75% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | BCMA (B-cell maturation antigen)Cell therapy | Myasthenia GravisDermatomyositis |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
2027 (2)
November 2027 (1)
What to watch
December 2027 (1)
What to watch
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0 | $16M | $125M | $11M-$28M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0 | $20M | $149M | —-$21M operating cash flow | report ↗ |
| 2026-Q1 | $0 | $19M | $120M | $39M-$22M operating cash flow | report ↗ |
| 2025-Q3 | $0 | $14M | $145M | $36M-$16M operating cash flow | report ↗ |
| 2025-Q2 | $0 | $15M | $162M | —-$18M operating cash flow | report ↗ |
| 2025-Q1 | $0.4M | $15M | $182M | $18M-$23M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $11M | $221M | $24M$14M operating cash flow | report ↗ |
| 2024-Q2 | $33M | $13M | $89M | —-$14M operating cash flow | report ↗ |
| 2024-Q1 | $5.8M | $9.7M | $105M | $57M-$16M operating cash flow | report ↗ |
| 2023-Q3 | $6.5M | $13M | $81M+ $0 short-term inv. | $9.0M-$9.2M operating cash flow | report ↗ |
| 2023-Q2 | $5.3M | $18M | $115M+ $0 short-term inv. | $11M-$9.9M operating cash flow | report ↗ |
| 2023-Q1 | $5.9M | $19M | $128M+ $0 short-term inv. | $22M-$8.8M operating cash flow | report ↗ |
| 2022-Q3 | $21M | $17M | $114M+ $34M short-term inv. | $7.9M$4.3M operating cash flow | report ↗ |
| 2022-Q2 | $39M | $19M | $139M+ $4.0M short-term inv. | —-$12M operating cash flow | report ↗ |
| 2022-Q1 | $34M | $18M | $115M+ $4.0M short-term inv. | —-$12M operating cash flow | report ↗ |
| 2021-Q3 | $24M | $21M | $116M+ $24M short-term inv. | $18M-$11M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0.4M | $58M | $127M | $33M-$74M operating cash flow | report ↗ |
Cartesian Therapeutics reported revenue of $0.4M, down 99.0% YoY, with R&D spend of $58.03M, up 28.6% YoY. The company held $126.87M in cash and equivalents and recorded a net loss of $130.3M, with a quarterly net burn of $130.3M.
The company noted its cash position is expected to fund operations into mid-2027, including completion of the Phase 3 AURORA trial of Descartes-08 in myasthenia gravis. Enrollment in AURORA continues, the Phase 2 TRITON trial in myositis is expected to initiate in 1H26, and the Phase 1/2 HELIOS pediatric trial is actively enrolling. Cartesian also highlighted recent Nature Medicine publications on Descartes-08 and board of directors appointments.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $38M | $45M | $214M | $19M-$24M operating cash flow | report ↗ |
| 2023-FY | $26M | $72M | $78M+ $0 short-term inv. | $55M-$51M operating cash flow | report ↗ |
| 2022-FY | $111M | $72M | $108M+ $28M short-term inv. | —-$32M operating cash flow | report ↗ |
| 2021-FY | $85M | $69M | $115M+ $14M short-term inv. | $6.4M-$60M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($206K), 3 sales ($259K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-04-02 | Kalayoglu Murat · 10% owner | Option exercise | 758,001 | — | — | Form 4 |
| 2026-04-02 | Hoge Elizabeth; Seven One Eight Three Four Irrevocable Trust · 10% owner; 10% owner | Option exercise | 758,001 | — | — | Form 4 |
| 2026-04-02 | Kalayoglu Murat · 10% owner | Option exercise (derivative) | 22,740.03 | — | — | Form 4 |
| 2026-04-02 | Hoge Elizabeth; Seven One Eight Three Four Irrevocable Trust · 10% owner; 10% owner | Option exercise (derivative) | 22,740.03 | — | — | Form 4 |
| 2026-03-13 | Singer Michael · director | Gift | 6,555 | — | — | Form 4 |
| 2026-01-06 | Davis Blaine · Chief Financial Officer | Open-market sale | 10,591 | $6.82 | $72K | Form 4 |
| 2026-01-06 | Miljkovic Milos · Chief Medical Officer | Open-market sale | 3,573 | $6.82 | $24K | Form 4 |
| 2026-01-06 | Brunn Carsten · director, President and CEO | Open-market sale | 23,766 | $6.82 | $162K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 83 reporting institutions held 7.2M shares ($43.7M, 23.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Squarepoint Ops LLC | 2,238,486 | $13.8M |
| 2 | FMR LLC | 799,743 | $4.9M |
| 3 | BlackRock, Inc. | 599,108 | $3.7M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 407,597 | $2.5M |
| 5 | 683 Capital Management, LLC | 330,000 | $2.0M |
| 6 | MILLENNIUM MANAGEMENT LLC | 284,317 | $1.7M |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 263,694 | $1.6M |
| 8 | MARSHALL WACE, LLP | 251,115 | $1.5M |
| 9 | Erste Asset Management GmbH | 221,705 | $1.3M |
| 10 | STATE STREET CORP | 200,337 | $1.2M |
| 11 | Privium Fund Management B.V. | 179,114 | $1.1M |
| 12 | TWO SIGMA INVESTMENTS, LP | 167,313 | $1.0M |
| 13 | UBS Group AG | 136,840 | $842K |
| 14 | CITADEL ADVISORS LLC | 110,128 | $677K |
| 15 | JACOBS LEVY EQUITY MANAGEMENT, INC | 101,534 | $624K |